Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared a post on X:
“Pleased to share our study published in Clinical Cancer Research.
NF2 loss (merlin deficiency) in RCC delineates a distinctly aggressive biological phenotype: heightened proliferative capacity, profound immune dysregulation, and recurrent alterations in cell cycle and DNA damage-response pathways.
Limited efficacy of immunotherapy further underscores the pressing need for biomarker-driven, molecularly tailored therapeutic strategies.”
Title: Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
Authors: Emre Yekedüz, Weiwei Bian, Stephanie E. Siegmund, Marc Machaalani, Jad El Masri, Mustafa Saleh, Eddy Saad, Liliana Ascione, Razane El Hajj Chehade, Clara Steiner, Pablo Moura Barrios, Stephanie A. Berg, Bradley McGregor, Charlene Mantia, Praful Ravi, Wenxin Xu, Michelle S. Hirsch, Toni K. Choueiri, Michael Serzan
Read The Full Article
Other articles about NF2 on OncoDaily.